The effect of supplementation of omega-3 and zinc on the treatment of type 2 diabetes

The effect of supplementation of omega-3 and zinc on liver and kidney parameters in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180201038585N1

Enrollment

Registered

2018-03-10

Start date

2016-09-30

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus

Interventions

Intervention 1: Intervention group: Group A = Intervention with omega-3 at a dose of 1000 mg daily one number capsule for 8 weeks - Dana Pharmaceutical Company. Intervention 2: Intervention group: Gro

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adults with Type 2 Diabetes

Exclusion criteria

Exclusion criteria: Insulin injection Pregnancy and lactation Pancreatic cancer

Design outcomes

Primary

Measure	Time frame
Alanine aminotransferase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Aspartate aminotransferase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Gamma glutamyl transpeptidase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Alkaline phosphatase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Creatinine. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.;Uric acid. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.;Urea. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.	—

Measure

Time frame

Alanine aminotransferase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Aspartate aminotransferase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Gamma glutamyl transpeptidase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Alkaline phosphatase. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method-IU/Lit.;Creatinine. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.;Uric acid. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.;Urea. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKarim Parastouei

Bagheiat-allah University of Medical Sciences

parastouei@gmail.com+98 21 8804 0060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026